Study of an experimental drug for multiple sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests an experimental drug called RO7121932 in people with multiple sclerosis. The goal is to see how safe it is and how the body processes it. It might help by offering a new way to manage the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of relapsing or progressive multiple sclerosis
- Your disability level is moderate, with an EDSS score of up to 7
- You are not currently taking any approved MS medications and agree not to start during the study
- You have not had more than one relapse in the last year or any relapse in the past 3 months
- You have not recently been treated with certain MS drugs like natalizumab, or B-cell therapies like ocrelizumab or rituximab within the past year
- You do not have other serious conditions such as active infections, cancer, or epilepsy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
This trial tests an experimental oral drug called VT7208 in both healthy volunteers and people with multiple sclerosis (MS). The goal is to see if it is safe and how the body processes it, which could lead to a new treatment option for MS.
This study tests whether a medicine that targets a specific brain inflammation marker (TSPO) can help in people with certain types of multiple sclerosis. It focuses on safety and whether the target can be measured and influenced during treatment.
This trial tests a new cell therapy called SYS6020 for people with multiple sclerosis that has not improved with standard treatments. The goal is to see if it can slow or stop the disease and improve symptoms.
This study compares a new drug called PB018 with the approved MS drug Ocrevus. Researchers want to see if PB018 works similarly and is safe for people with relapsing or progressive forms of MS.
This trial tests if ofatumumab can help people with relapsing multiple sclerosis (RMS) by measuring its effect on nerve damage markers in the blood. It aims to see if the drug is safe and effective for controlling relapses and slowing disease activity.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.